CN105377282B - 环炔衍生化的糖 - Google Patents

环炔衍生化的糖 Download PDF

Info

Publication number
CN105377282B
CN105377282B CN201480012960.8A CN201480012960A CN105377282B CN 105377282 B CN105377282 B CN 105377282B CN 201480012960 A CN201480012960 A CN 201480012960A CN 105377282 B CN105377282 B CN 105377282B
Authority
CN
China
Prior art keywords
saccharide
conjugate
azide
group
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480012960.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377282A (zh
Inventor
R.阿达莫
F.伯蒂
胡琦颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN105377282A publication Critical patent/CN105377282A/zh
Application granted granted Critical
Publication of CN105377282B publication Critical patent/CN105377282B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480012960.8A 2013-01-15 2014-01-13 环炔衍生化的糖 Active CN105377282B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1300707.5 2013-01-15
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (2)

Publication Number Publication Date
CN105377282A CN105377282A (zh) 2016-03-02
CN105377282B true CN105377282B (zh) 2020-07-17

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012960.8A Active CN105377282B (zh) 2013-01-15 2014-01-13 环炔衍生化的糖

Country Status (16)

Country Link
US (3) US11135300B2 (https=)
EP (1) EP2945641B1 (https=)
JP (3) JP6719209B2 (https=)
CN (1) CN105377282B (https=)
BR (1) BR112015016817B1 (https=)
CA (1) CA2897348C (https=)
CY (1) CY1122822T1 (https=)
DK (1) DK2945641T3 (https=)
ES (1) ES2774729T3 (https=)
GB (1) GB201300707D0 (https=)
HR (1) HRP20200351T1 (https=)
LT (1) LT2945641T (https=)
PL (1) PL2945641T3 (https=)
PT (1) PT2945641T (https=)
SI (1) SI2945641T1 (https=)
WO (1) WO2014111344A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
SG11201807430WA (en) * 2016-03-04 2018-09-27 Euglena Co Ltd Antiviral agent and antiviral food
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
JP7295571B2 (ja) * 2018-02-05 2023-06-21 国立大学法人 宮崎大学 細胞標識剤及び細胞標識キット
CN116874636B (zh) 2018-06-14 2026-04-17 持田制药株式会社 新型交联海藻酸
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
MX2023013434A (es) * 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
JP7804631B2 (ja) * 2022-11-22 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304765A (zh) * 2005-02-01 2008-11-12 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
CN101925366A (zh) * 2007-11-21 2010-12-22 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
WO2011136645A1 (en) * 2010-04-27 2011-11-03 Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen Fused cyclooctyne compounds and their use in metal-free click reactions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1777236T (pt) * 2002-03-26 2017-02-13 Glaxosmithkline Biologicals Sa Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
EP1812057A4 (en) 2004-11-01 2009-07-22 Brigham & Womens Hospital Modified Streptococci polysaccharides and their uses
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
US8765920B2 (en) * 2009-12-23 2014-07-01 The Scripps Research Institute Tyrosine bioconjugation through aqueous Ene-like reactions
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2621905B1 (en) 2010-09-27 2017-04-12 University Of Georgia Research Foundation, Inc. Methods including latent 1,3-dipole-functional compounds and materials prepared thereby
US20120208722A1 (en) * 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
WO2013078562A2 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304765A (zh) * 2005-02-01 2008-11-12 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
CN101925366A (zh) * 2007-11-21 2010-12-22 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
WO2011136645A1 (en) * 2010-04-27 2011-11-03 Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen Fused cyclooctyne compounds and their use in metal-free click reactions

Also Published As

Publication number Publication date
JP6719209B2 (ja) 2020-07-08
US20210268116A1 (en) 2021-09-02
US20260027216A1 (en) 2026-01-29
PT2945641T (pt) 2020-03-26
JP7036854B2 (ja) 2022-03-15
BR112015016817B1 (pt) 2020-11-10
CA2897348C (en) 2022-09-27
CY1122822T1 (el) 2021-05-05
US12409231B2 (en) 2025-09-09
JP2016506905A (ja) 2016-03-07
CN105377282A (zh) 2016-03-02
SI2945641T1 (sl) 2020-03-31
ES2774729T3 (es) 2020-07-22
DK2945641T3 (da) 2020-03-09
PL2945641T3 (pl) 2020-06-15
EP2945641B1 (en) 2020-01-01
BR112015016817A8 (pt) 2019-10-29
US11135300B2 (en) 2021-10-05
JP2020114839A (ja) 2020-07-30
LT2945641T (lt) 2020-02-25
WO2014111344A1 (en) 2014-07-24
CA2897348A1 (en) 2014-07-24
EP2945641A1 (en) 2015-11-25
JP2019073528A (ja) 2019-05-16
GB201300707D0 (en) 2013-02-27
US20160166704A1 (en) 2016-06-16
HRP20200351T1 (hr) 2020-06-12
BR112015016817A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
CN105377282B (zh) 环炔衍生化的糖
JP7268125B2 (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
JP5818826B2 (ja) 連鎖球菌性莢膜糖の複合
JP5590760B2 (ja) 低アセチル化または高アセチル化された髄膜炎菌の莢膜糖類
JP6093302B2 (ja) 免疫原性組成物
JP6266000B2 (ja) 免疫原性組成物
JP6170932B2 (ja) spr0096抗原およびspr2021抗原を含むキャリア分子
JP2014144984A (ja) 髄膜炎菌結合体ワクチン接種
KR20150060986A (ko) 비선형 사카라이드 컨주게이트
TWI919324B (zh) 包含結合之莢膜醣抗原的免疫原組合物及其用途
TW202600584A (zh) 包含結合的莢膜醣抗原的免疫原性組合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant